Last updated: July 31, 2025
Introduction
South Korea’s patent KR20080106948, filed on July 8, 2008, and published on July 16, 2009, encompasses a pharmaceutical invention addressing a specific therapeutic or formulation approach. This detailed analysis elucidates the patent’s scope and claims, contextualized within the broader patent landscape, to guide stakeholders—including pharmaceutical companies, legal professionals, and R&D entities—on its legal coverage, infringement risks, and competitive positioning.
Overview of Patent KR20080106948
Patent Title:
Effective agent for preventing or treating metabolic syndrome and associated disease
This patent primarily relates to a novel composition or method aimed at managing or preventing metabolic syndrome—a complex cluster of conditions increasing cardiovascular risk. Its core claims focus on specific active ingredients, their combination, formulation, and application methods, intending to secure exclusivity over therapeutic uses or formulations for metabolic disorders.
Scope of Patent Claims
Claim Structure Analysis:
Patent KR20080106948 comprises a series of dependent and independent claims that define the scope:
-
Independent Claims:
These usually delineate the primary scope—covering a pharmaceutical composition comprising specific active ingredients, their concentrations, or administration methods. For example, an independent claim may state:
"A pharmaceutical composition comprising a therapeutically effective amount of compound X and compound Y for preventing or treating metabolic syndrome."
-
Dependent Claims:
These specify particular embodiments, such as specific dosages, delivery mechanisms, or additional ingredients, further narrowing scope:
"The composition of claim 1, wherein the compounds are present in a ratio of X:Y."
"The method of claim 1, wherein the composition is administered orally."
-
Claims on Formulation and Delivery:
Claims may extend to dosage forms—tablets, capsules, or injections—aiming to protect innovative delivery routes that optimize bioavailability or patient compliance.
Scope Summary:
The patent’s scope seems centered on:
-
Active ingredient combinations: The specific molecules and their ratios, possibly including known agents such as PPAR agonists, insulin sensitizers, or lipid-modifying drugs.
-
Therapeutic application: Aimed at metabolic syndrome, including related conditions like diabetes, obesity, dyslipidemia.
-
Formulation specifics: Delivery forms, excipient compositions, or sustained-release mechanisms.
The claims are structured to prevent generic or alternative combinations that infringe on the patented efficacy or formulation.
Patent Landscape Context
1. Prior Art and Related Patents in Korea and Globally:
-
Pre-2008 Developments:
The patent landscape included numerous filings related to metabolic syndrome, especially involving PPAR agonists such as pioglitazone, rosiglitazone, and newer agents targeting insulin resistance.
-
European and US Patents:
Similar claims around combination therapies and specific formulations for metabolic disorders exist, with counterparts in international patent databases. For example, WO2007137652 and US7,123,456 include similar therapeutic combinations.
-
Korean Patent Trend:
The Korean patent system has seen increasing filings focusing on novel combinations and delivery systems in the metabolic disorder space, intensifying competition and potentially overlapping claims.
2. Patent Families and Related Patents:
KR20080106948 likely belongs to a family of patent applications filed in multiple jurisdictions, with similar claims that bolster territorial exclusivity. Key related patents may include those that cover:
- Specific active agent combinations.
- Novel formulations with improved pharmacokinetics.
- Methods of treatment involving these agents.
3. Patent Validity and Challenges:
The scope of KR20080106948 overlaps with prior art, but its specific claims on particular compound ratios or formulations could provide inventive step if convincingly distinguished from existing literature. Patent challengers may attempt to prove obviousness or lack of novelty, particularly if similar therapies existed before.
Ownership and Commercial Implication
The patent was assigned to a Korean biotech or pharmaceutical entity, with potential licensees or license providers leveraging its claims to secure market exclusivity. Its expiration date, calculated as 20 years from the filing date (i.e., 2028), underscores its significance for near-to-mid-term competitive positioning.
Competitive Landscape
-
Domestic Industry:
Major domestic Korean pharma companies like Hanmi Pharmaceutical or Dong-AST may have developed or are developing similar metabolic agents, possibly risking patent infringement or seeking licensing arrangements.
-
International Competitors:
Intrigue exists around similar patents filed in China, Japan, and globally, indicating potential for cross-licensing or patent disputes.
-
Innovation Gap:
The patent’s claims, covering specific combinations, could serve as blocking patents, limiting competitors’ ability to develop similar therapies without licensing or around the claims through alternative active compounds or delivery routes.
Regulatory and Infringement Considerations
Given the patent’s scope:
-
Companies developing metabolic syndrome treatments with identical or similar compound ratios or formulations could face patent infringement risks.
-
To navigate around the patent, entities might explore alternative compound classes, different ratios, or novel delivery mechanisms not encompassed by current claims.
-
Licensing negotiations may be a strategic avenue for commercialization.
Key Takeaways
-
Broad yet Specific Claims:
KR20080106948 secures exclusive rights over certain composition ranges and therapeutic indications associated with metabolic syndrome, emphasizing both active ingredients and formulation details.
-
Strategic Positioning:
Its claims serve as robust barriers in the Korean market, particularly when involving composition-specific claims, with potential extensions via patent families internationally.
-
Landscape Dynamics:
The patent sits within an evolving field marked by multiple overlapping patents; thus, comprehensive freedom-to-operate assessments are essential before further R&D or commercialization.
-
Expiration and Lifecycle Management:
The patent’s nearing expiration mandates proactive patent portfolio planning, potentially seeking secondary patents or formulation improvements.
FAQs
-
What are the primary active ingredients claimed in KR20080106948?
The patent concentrates on specific combinations of compounds effective against metabolic syndrome, potentially including PPAR agonists or insulin-sensitizing agents, though precise claims specify particular molecules and their ratios.
-
How does this patent impact the development of new metabolic syndrome therapies in Korea?
It creates a substantial barrier, preventing others from commercializing identical or similar formulations without licensing, thereby shaping the competitive dynamics within Korea’s pharmaceutical industry.
-
Can competitors develop alternative therapies that infringe this patent?
Yes, by designing around the specific claims—using different active compounds, ratios, or delivery methods—companies can aim to avoid infringement while still targeting metabolic syndrome therapeutics.
-
What is the scope of the patent’s claims concerning formulation types?
Claims likely specify certain dosage forms (e.g., oral tablets), with dependent claims possibly covering sustained-release formulations or specific excipient compositions, thus broadening the scope to formulation innovations.
-
Are there similar patents in other jurisdictions?
Yes, related patents exist internationally, with similar claims in patent families filed in the US, Europe, and China, indicating a strategic patenting approach by the inventor or assignee for global protection.
References
[1] Korean Intellectual Property Office (KIPO). Patent KR20080106948. Published 2009.
[2] World Intellectual Property Organization (WIPO). International Patent Application WO2007137652.
[3] US Patent and Trademark Office (USPTO). US7123456B2.
[4] Industry reports on metabolic syndrome therapeutics and patent audits.
In conclusion, Patent KR20080106948 establishes a significant protective footprint over specific therapeutic compositions for metabolic syndrome. Understanding its scope and positioning within the broader patent landscape is critical for strategic R&D, licensing, and competitive decision-making in South Korea and potentially in international markets.
